



UNIVERSIDADE DA BEIRA INTERIOR
Ciências da Saúde

**Clinical Characterization of Parkinson's Disease
Patients Followed at CHCB
Comparison with a control group**

Patrícia Valério dos Santos

Dissertação para obtenção do Grau de Mestre em
Medicina
(ciclo de estudos integrado)

Orientador: Prof. Doutor Graça Maria Fernandes Baltazar
Coorientador: Prof. Doutora Maria Luiza Rosado

Covilhã, maio de 2014

Clinical Characterization of Parkinson's Disease Patients Followed at CHCB:
Comparison with a control group

Acknowledgments

Apesar da solidão que caracteriza a redação de uma dissertação de mestrado, há contributos, ao longo do meu percurso, que não podem ser esquecidos.

À Prof^a. Doutora Graça Maria Fernandes Baltazar, minha orientadora, pelo acompanhamento e organização deste trabalho, pela disponibilidade e dedicação reveladas, sem os quais esta investigação não seria possível.

À Prof^a. Doutora Luiza Rosado, minha coorientadora, a quem agradeço sinceramente a disponibilidade, dedicação e apoio, essenciais à concretização deste trabalho.

À Dra. Andreia Monteiro, Dra. Débora Rodrigues e restantes profissionais do Laboratório de Patologia Clínica, cujo contributo foi indispensável.

À equipa médica de Neurologia do Centro Hospitalar da Cova da Beira, que contribuíram para o crescimento e enriquecimento deste trabalho.

Aos profissionais do sector 1 da Consulta Externa do Centro Hospitalar da Cova da Beira, pela disponibilidade e apoio prestados.

À equipa médica de Urologia e ao Dr. Humberto Gonçalves, pela disponibilidade e apoio concedidos à minha proposta.

À Rita Videira e restantes estudantes e profissionais do CICS, pelo incansável apoio numa área tão desconhecida para mim.

À Prof^a. Mafalda Fonseca e Prof^a. Olga Lourenço, pelo apoio crucial a este projeto.

Ao Mauro Sousa, por em todos os momentos me inspirar e motivar a ser e fazer sempre melhor.

À Vânia Pinto, pelos momentos passados juntos na construção do nosso futuro.

À Mélina Lopes, pelo apoio incondicional nos momentos de maior desalento.

Às minhas amigas, por acreditarem em mim.

À minha família pela motivação constante.

A todos os participantes deste estudo.

Clinical Characterization of Parkinson's Disease Patients Followed at CHCB:
Comparison with a control group

Abstract

Parkinson's disease is the second most common neurodegenerative disease, characterized by four motor symptoms: rest tremor, bradykinesia, rigidity and postural instability. Diagnosis is made through strict clinical criteria, but clinical diagnosis is difficult in the early disease state and frequently does not allow a definitive diagnosis. One hallmark of Parkinson's disease is the death of the pigmented dopaminergic neurons of midbrain *substantia nigra*, with consequent loss of the neurotransmitter dopamine in the corpus striatum. The exact mechanisms underlying are still not understood and current theories include neuroinflammation and oxidative stress. Evidences suggest the presence of chronically activated microglia and several studies detected higher levels of their markers, namely cytokines and oxidative stress products. The main objectives of this study were to characterize CHCB's Parkinson population, to evaluate inflammatory and oxidative markers and immunological status.

Medical records were evaluated for patients (n=38) and healthy controls (n=32). Patient's motor symptoms at onset and at evaluation were determined. The inflammatory markers measured were C reactive protein, erythrocyte sedimentation rate and serum cytokines (interleukins 1B, 8, 6, 10, 12p70 and Tumor Necrosis Factor). Immunological status was accessed through leukogram. Urate was our oxidative marker.

The cytokines measurement reveals values below the lower limits of detection for all. C reactive protein was higher in patients, but erythrocyte sedimentation rate was similar between both groups. In leukogram analysis, we detected higher values of neutrophils in patients. However, lymphocytes were the only that decrease throughout the temporal evolution of the disease and in patients using higher doses of L-DOPA. We attempted to clarify the real cause of lymphocytes decrease. Although there was a tendency to observe a lower number of lymphocytes for higher doses of L-DOPA in all phases of temporal evolution of the disease, the difference was not statistically significant. In relation to urate, we obtained lower values in patients and the decrease was marked in the higher stages of the disease and longer disease duration.

Regarding inflammatory aspects of the disease, our study showed that cytokine pattern is not sensitive or specific to assess disease progression. On the other hand, the antioxidant urate presents us as a putative marker of disease severity.

Keywords

Biomarkers

Cytokines

Lymphocytes

Oxidative stress

Parkinson's disease

Resumo

A doença de Parkinson é a segunda doença neurodegenerativa mais comum, caracterizando-se por quatro sintomas motores: tremor de repouso, bradicinesia, rigidez e instabilidade postural. O diagnóstico é feito através de rigorosos critérios clínicos, mas o diagnóstico clínico é difícil na fase inicial da doença e, frequentemente, não permite o diagnóstico definitivo. A Doença de Parkinson consiste na morte dos neurónios dopaminérgicos pigmentados da *substantia nigra* do mesencéfalo, com conseqüente perda do neurotransmissor dopamina no corpo estriado. Os mecanismos exatos subjacentes ainda não são compreendidos e as teorias atuais incluem mecanismos inflamatórios e de *stress* oxidativo. Evidências sugerem a presença de microglia cronicamente ativada, com diversos estudos mostrando níveis elevados de marcadores da microglia, nomeadamente citocinas e produtos de *stress* oxidativo. Os principais objetivos deste estudo foram caracterizar a população de doentes do CHCB, avaliar os seus marcadores inflamatórios e oxidativos e o seu estado imunológico.

Os processos clínicos foram avaliados para os doentes (n = 38) e controlos (n = 32). Os sintomas motores dos doentes no início da doença e no dia da avaliação foram registados. Os marcadores inflamatórios medidos foram a proteína-C-reativa, a velocidade de hemossedimentação e citocinas séricas (interleucinas 1B, 8, 6, 10, 12p70 e Fator de Necrose Tumoral). O sistema imunológico foi avaliado através do leucograma e o ácido úrico foi o marcador oxidativo utilizado.

A medição das citocinas revelou valores abaixo dos limites inferiores de deteção. A proteína-C-reativa foi superior nos doentes, mas a velocidade de hemossedimentação foi semelhante entre os grupos. Na análise do leucograma, detetamos valores superiores de neutrófilos nos doentes. No entanto, os linfócitos foram os únicos que diminuíram com a evolução temporal da doença e nos indivíduos que utilizavam maiores doses de L-DOPA. Na tentativa de esclarecer a verdadeira causa dessa diminuição, detetámos que, embora houvesse uma tendência a se observar um menor número de linfócitos para altas doses de L-DOPA em todas as fases de evolução temporal da doença, a diferença não foi estatisticamente significativa. Em relação ao ácido úrico, obtiveram-se valores menores nos doentes, sendo a diminuição superior nos estágios mais elevados e na maior duração da doença.

Relativamente aos aspetos inflamatórios da doença, os nossos resultados mostraram que o padrão de citocinas não é sensível ou específico para avaliação da progressão da doença. Por outro lado, o ácido úrico apresenta-se como um possível marcador da severidade da doença.

Palavras-chave

Biomarcadores

Citoquinas

Doença de Parkinson

Linfócitos

Stress oxidativo

Resumo alargado

A doença de Parkinson é a segunda doença neurodegenerativa mais comum, caracterizando-se por quatro sintomas motores: tremor de repouso, bradicinesia, rigidez e instabilidade postural. A existência de uma fase pré-motora deve orientar a busca de biomarcadores específicos e identificação de fatores de risco e de proteção. O diagnóstico é feito através de rigorosos critérios clínicos, mas o diagnóstico clínico é difícil na fase inicial da doença. A doença de Parkinson consiste na morte dos neurónios dopaminérgicos pigmentados da *substantia nigra pars compacta* do mesencéfalo, com consequente perda do neurotransmissor dopamina no corpo estriado, um dos núcleos subcorticais envolvidas no controlo do movimento. Os mecanismos exatos subjacentes ainda não são compreendidos e as teorias atuais incluem mecanismos inflamatórios e de *stress* oxidativo. Evidências sugerem a presença de microglia cronicamente ativada, com diversos estudos mostrando níveis elevados de marcadores da microglia, nomeadamente citocinas e produtos de *stress* oxidativo. Os principais objetivos deste estudo foram caracterizar a população de doentes do CHCB, avaliar os seus marcadores inflamatórios e oxidativos e o seu estado imunológico.

Para todos os doentes de Parkinson (n=38), relativamente à clínica, foram registadas as seguintes variáveis: idade de início da doença, gravidade da doença (através da escala modificada de Hoehn & Yahr para estadiamento e dos anos de duração da doença), dose de L-DOPA de libertação imediata atualmente em utilização, sintomas inaugurais da doença e sintomas no dia da avaliação. Os processos clínicos foram avaliados para os doentes e controlos (n = 32). Os marcadores inflamatórios medidos foram a proteína-C-reativa, a velocidade de hemossedimentação e citocinas séricas (interleucinas 1B, 8, 6, 10, 12p70 e Fator de Necrose Tumoral). O sistema imunológico foi avaliado através do leucograma e o ácido úrico foi o marcador oxidativo utilizado. O hemograma também foi incluído para uma melhor caracterização da população do estudo. As citocinas no soro foram medidas através do *kit* BD™ CBA Human Inflammatory Cytokines, através de citometria de fluxo, no laboratório do Centro de Investigação em Ciências da Saúde (CICS), da Universidade da Beira Interior. Os restantes parâmetros analíticos foram obtidos através das análises de rotina prescritos pelo médico responsável pelo respetivo doente, no Hospital Pêro da Covilhã.

A nossa população de doentes é composta maioritariamente por homens, com média de idade de início da doença de 73,8 anos, sendo uma população com mais comorbilidades associadas, em comparação com os controlos. A maioria dos doentes apresentou tremor como sintoma inicial, mas a rigidez foi o mais prevalente na avaliação. A medição citocinas revelou valores abaixo dos limites inferiores de deteção. A proteína-C-reativa foi superior nos doentes, mas a velocidade de hemossedimentação foi semelhante entre os grupos. Na análise do leucograma,

detetamos valores superiores de neutrófilos nos doentes. No entanto, os linfócitos foram os únicos que diminuíram com a evolução temporal da doença e nos indivíduos que utilizavam maiores doses de L-DOPA. Na tentativa de esclarecer a verdadeira causa dessa diminuição, detetámos que, embora houvesse uma tendência a se observar um menor número de linfócitos para altas doses de L-DOPA em todas as fases de evolução temporal da doença, a diferença não foi estatisticamente significativa. Em relação ao ácido úrico, obtiveram-se valores menores nos doentes, especialmente para a população masculina, sendo a diminuição superior nos estágios mais elevados e na maior duração da doença. Por último, o hemograma mostrou níveis de hemoglobina mais baixos para os doentes, principalmente na população feminina.

Relativamente aos aspetos inflamatórios da doença, os nossos resultados mostraram que o padrão de citocinas não é o sensível ou específico para avaliação da progressão da doença, sendo os resultados muito inconsistentes. Por outro lado, o ácido úrico apresenta-se como um possível marcador da severidade da doença.

Index

Acknowledgment.....	iii
Abstract.....	v
Resumo	vii
Resumo alargado.....	ix
List of Figures	xiii
List of Tables	xv
List of Acronyms	xvii
1. Introduction.....	1
1.1. Neuroinflammation.....	2
1.2. Oxidative stress.....	2
1.3. Objectives.....	3
2. Materials and Methods	5
2.1. Patients.....	5
2.2. Controls	7
2.3. Ethical Approval	7
2.4. Exclusion Criteria	7
2.5. Sample collection.....	8
2.6. Sample analysis	8
2.7. Statistical analysis.....	9
2.8. Data Analysis	10
3. Results	11
3.1. Patient recruitment	11
3.2. Demographic characteristics of study population.....	11
3.3. Clinical characteristics of PD patients	11
3.4. Inflammatory parameters	14
3.4.1. Cytokine measurement with BDCBAHICK	14
3.4.2. Biochemical parameters.....	15
3.5. Leukogram parameters	16
3.6. Oxidative parameters	18
3.7. Hemogram parameters	20
4. Discussion	21
References	Erro! Marcador não definido.
Appendix	31

Clinical Characterization of Parkinson's Disease Patients Followed at CHCB:
Comparison with a control group

List of Figures

Figure 1 - Hypothesized disease course of PD.....	1
Figure 2 - United Kingdom Parkinson's Disease Society Brain Bank Criteria (UKPDBBC) for PD diagnosis.....	6
Figure 3 - Modified Hoehn & Yahr staging scale (mH&Yss).	6
Graph 1 - Cardinal symptoms at onset..	13
Graph 2 - Cardinal symptoms at evaluation	13
Graph 3 - mH&Yss distribution of PD patients.	14
Graph 4 - eGFR from PD and HC groups: females (a) and males (b) - scatter plot graphs.	16
Graph 5 - Neutrophils from PD and HC groups - scatter plot graphs.	17
Graph 6 - Hb from PD and HC groups: females (a) and males (b) - scatter plot graphs.	20

Clinical Characterization of Parkinson's Disease Patients Followed at CHCB:
Comparison with a control group

List of Tables

Table 1 - Sample analysis performed.	9
Table 2 - Variables investigated.	10
Table 3 - Gender distribution of study population.	11
Table 4 - Age distributions of study population.....	11
Table 5 - PD group medical history, with main comorbidities represented.....	12
Table 6 - Clinical features of PD patients.....	12
Table 7 - LLOD for each cytokine, according with BDCBAHICK Instruction Manual.	15
Table 8 - Median FI obtained for PD and HC groups. All cytokines measured were below the LLOD.....	15
Table 9 - Inflammatory parameters of PD and HC groups.....	15
Table 10 - eGFR of PD and HC groups, according with gender.....	16
Table 11 - Leukogram parameters of PD and HC groups.	17
Table 12 - Analysis of lymphocyte number in patients, according with Disease Duration.	18
Table 13 - Analysis of lymphocyte number in patients, according with L-DOPA Dose.	18
Table 14 - Crossed Disease Duration and L-DOPA Dose subgroups: comparison between L-DOPA Dose subgroups lymphocytes, according to disease duration.	18
Table 15 - Urate values of PD and HC groups, according with gender.....	19
Table 16 - Comparison between urate levels of male and females from PD group, according with Disease Stage.	19
Table 17 - Comparison between urate levels of male and females from PD group, according with Disease Duration.	19
Table 18 - Comparison between urate levels of male and females from Early Stage PD subgroup and HC group.	19
Table 19 - Hemogram parameters of PD and HC groups.	20

Clinical Characterization of Parkinson's Disease Patients Followed at CHCB:
Comparison with a control group

List of Acronyms

AC	Absolute count
BDCBAHICK	BD™ CBA Human Inflammatory Cytokines Kit
CBA	Cytometric Bead Array
CDK-EPI	Chronic Kidney Disease Epidemiology Collaboration
CHCB	Centro Hospitalar da Cova da Beira
CICS	Centro de Investigação em Ciências da Saúde
CKD	Chronic kidney disease
CNS	Central nervous system
COMT	Catechol-O-methyl transferase
Cr	Serum creatinine
CRP	C reactive protein
CSF	Cerebrospinal fluid
DM	Diabetes Mellitus
DN	Dopaminergic neurons
EDTA	Ethylenediamine tetraacetic acid
eGFR	Estimate glomerular filtrate rate
ER	Extended release
ESR	Erythrocyte sedimentation rate
F	Female
FI	Fluorescence intensity
Hb	Hemoglobin
HC	Healthy controls
HTA	Hypertension
IL	Interleukin
IR	Immediate release
LBs	Lewy bodies
LLOD	Low limit of detection
LNs	Lewy neurites
M	Male
MAO	Monoamine oxidase
MCHC	Mean corpuscular hemoglobin concentration
MCV	Mean corpuscular volume
mH&Yss	Modified Hoehn & Yahr staging scale
NMDA	N-methyl-D-aspartate
NSAIDs	Non-steroids anti-inflammatory drugs
PD	Parkinson's disease
RDW	Red Cell Distribution Width
ROS	Reactive oxygen species
SN	<i>Substantia nigra</i>
SNpc	<i>Substantia nigra pars compacta</i>
TNF	Tumor necrosis factor
UKPDSBBC	UK Parkinson's Disease Society Brain Bank Criteria

Clinical Characterization of Parkinson's Disease Patients Followed at CHCB:
Comparison with a control group

1. Introduction

Parkinson's Disease (PD) is the second most common neurodegenerative disease (1, 2). PD, classically a motor disorder, is now recognized as a complex condition that includes neuropsychiatric and nonmotor symptoms¹ (3, 4). The four cardinal features of PD are the following motor symptoms: rest tremor, bradykinesia, rigidity and postural instability (3).

The existing data suggest that PD starts years before the appearance of the cardinal motor symptoms (preclinical stage), when several premotor symptoms may already be present (premotor stage) (Figure 1) (4, 5). Evidences suggests that premotor stage could extend from 3 to 20 years and its existence should guide the search for PD biomarkers and the identification of risk and protective factors (6).

Prenatal stage	Preclinical PD		Clinical PD	
	Pre symptomatic stage	Premotor stage	Possible PD	Confirmed PD
Genetic and/or environmental factors	Early neurodegenerative and compensatory changes	Non-motor symptoms. Possible neuroimaging, biological or physiological markers. (5)	Partial motor symptoms	Classic motor symptoms

Figure 1 - Hypothesized disease course of PD (4).

→ Dopaminergic neurons (DN); - - - → Clinical rating.

Nowadays PD diagnosis is made through strict clinical criteria. National Institute for Health and Care Excellence - NICE current guidelines (7) recommend United Kingdom Parkinson's Disease Society Brain Bank Criteria (UKPDSBBC) (Figure 2) (8). However, clinical diagnosis is difficult in the early disease state and frequently does not allow a definitive diagnose (8).

PD etiology remains largely unknown (1, 2, 9). About 5-10% of cases have genetic origin, with inheritable genetic mutations (2, 9). These are mainly atypical, with early onset and low prevalence of tremor (10). 95% are of idiopathic origin, although several risk factors have been identified² (2, 9).

PD results from the death of the pigmented dopaminergic neurons (DN) of midbrain *substantia nigra* (SN) *pars compacta* (SNpc), with consequent loss of the neurotransmitter dopamine in the corpus striatum, one of the subcortical nuclei involved in control of movement (2, 7, 9). Clinical symptoms emerge when approximately 50% of SNpc DN and 60-

¹ They include olfactory dysfunction; sleep disturbances; mood disorders; psychosis and hallucinations; dysautonomia; fatigue; cognitive dysfunction/dementia; pain and sensory disturbances.

² Such as, age (2, 9), genetic predisposition, environmental toxins, neuronal injury (such as traumatic brain injury or stroke) and bacterial or viral infections (9).

80% of the striatal dopamine were lost (2, 4), which begins during the preclinical stage (4). The nigral damage spreads to other brain regions like lower brainstem, olfactory bulb, autonomic nervous system and, in the severest cases, neocortex (11).

Another PD's hallmark is the presence of Lewy neurites (LNs) in cellular processes and Lewy bodies (LBs) in neuronal perikarya (11).

The exact mechanisms underlying DN degeneration are still not understood. Current theories include neuroinflammation, oxidative stress, mitochondrial dysfunction³ and disturbances of intracellular ions homeostasis. (12) These are compatible with the evidences that SN is very susceptible to microglia neurotoxicity and oxidative stress: SN has high density of microglia (9), high levels of iron (13), reduced level of intracellular antioxidant glutathione (14) and accumulates dopamine, which induces reactive oxygen species (ROS) through oxidation reactions (13, 15).

1.1. Neuroinflammation

Post-mortem studies revealed the first evidences of the presence of chronically activated microglia in SN (9, 16).

Microglia, the resident immune cells of central nervous system (CNS), is sensitive to minor microenvironment disturbances, becoming readily activated. Activated microglia has functional plasticity and they transform into a macrophage-like phenotype, which is maintained with continuous stimulation. Microglia activation mechanisms are not clearly understood. It could be indirectly through a positive feedback from degenerating neurons (reactive microgliosis), or directly due to a toxin, pathogen or endogenous protein⁴ (9).

Inflammatory markers from activated microglia, such as cytokines, are increased and they potentiate microglial activation (9, 12). Several studies detected higher levels of pro- and anti-inflammatory cytokines in PD patients' (cerebrospinal fluid) CSF (9) and peripheral blood than in healthy controls (HC) (9, 12, 17-19).

1.2. Oxidative stress

Post mortem and in vivo studies showed that PD brains present high levels of oxidative stress products (13).

Oxidative stress can be both a trigger and a maintainer of DN degeneration (13). Activated microglia further contributes to oxidative stress (13, 20), starting several responses to eliminate the source of inflammatory signals through it (13). On the other hand, ROS could stimulate production of pro-inflammatory cytokines by microglia (12, 13).

³ Particularly membrane lipid peroxidation.

⁴ Such as α -synuclein-aggregates, neuromelanin (9, 17), adenosine triphosphate and matrix metalloproteinase-3 (9).

1.3. Objectives

The development of a sensitive biomarker for PD diagnosis is an ambitious goal that could contribute to the identification of individuals at risk, earlier and accurate diagnosis, discrimination from atypical parkinsonism and tracking disease progression (4, 21). Currently many research groups are trying to identify reliable markers.

In this study, we proposed to develop a demographic and clinical characterization of PD population of Centro Hospitalar da Cova da Beira (CHCB) and, then, to evaluate several parameters presented by patients in different stages of the disease and to compare with HC, aiming to focus on the initial phases of the disease.

Inflammation markers, such as serum cytokines [interleukin (IL)-1 β , IL-8, IL-6, IL-10, Tumor Necrosis Factor (TNF), and IL-12p70], C reactive protein (CRP) and Erythrocyte sedimentation rate (ESR) were measured to determinate the magnitude of inflammation intervention in the disease. Immunological and oxidative status were accessed through leukogram and urate values, respectively. The haematological profile was also analysed.

Clinical Characterization of Parkinson's Disease Patients Followed at CHCB:
Comparison with a control group

2. Materials and Methods

2.1. Patients

The study was carried out with 38 PD patients, 21 males (55,3%) and 17 females (44,7%), with age between 55 and 86 years.

PD patients group were recruited from appointment list of CHCB (Covilhã - Portugal) Neurology sector, between January 2013 and December 2013.

Patients with clinical diagnosis of PD established by the UKPDBBC (Figure 2) (8) and modified Hoehn & Yahr staging scale (mH&Yss) (Figure 3) between 1 and 4 (22, 23) were included. Patients with recent and previous diagnosis (people who were followed for several years due to DP) were recruited.

All patients underwent an interview with a questionnaire (Annex 1), neurological examination performed by a neurologist, laboratory tests and medical record evaluation. A neurologist performed a neurological examination to apply mH&Yss (23) and to provide clinical data, by evaluating PD cardinal signs⁵. Interview and medical record evaluation allowed to obtain demographic and medical information including: duration of PD, early motor symptoms, actual motor symptoms, presence or absence of non-motor symptoms, mean daily dosage of L-DOPA, actual and previous PD medications, copies of brain imaging exams, comorbidities, additional medications and Emergency appointments.

Participants with Diabetes mellitus (DM), hypertension (HTA), coronary and heart disease, hyperlipidemia and thyroid disease were included, if treated with the appropriate medication and if there was no evidence of exacerbations or complications in the clinical records, in the past 6 months.

All documents were identified by a study number to maintain confidentiality.

⁵ Tremor is involuntary, rhythmic and, mainly, at rest. In limbs, when patient relaxes with hands on the lap it is possible evaluate tremor. It could also affect legs, lips, jaw or tongue. (24) Rigidity is characterized by increased resistance to passive movement about a joint, decreased arm swing with walking and the typical stooped posture (24). Bradykinesia is a generalized slowness of movement or even absence of movement (akinesia). It's evaluated through observation of facial hypomimia and limb movement, including speed, amplitude and rhythm of finger tapping, hand gripping, pronation-supination hand movements and heel or toe taping. Gait freezing and festination may develop in later disease. (24) "Pull" test evaluates postural instability: the examiner stands behind the patients and pulls the patients by his shoulders. Patients with postural instability take multiple steps backwards or could fall (positive "pull" test). Disease progression could lead to a festinant gait or confine the patient in a wheelchair, when postural reflexes are lost. (24)

<p>Step 1 - Diagnosis of parkinsonian Syndrome</p> <ul style="list-style-type: none">• Bradykinesia• At least one of the following:<ul style="list-style-type: none">– muscular rigidity– 4-6 Hz rest tremor– postural instability not caused by primary visual, vestibular, cerebellar, or proprioceptive dysfunction
<p>Step 2 - Exclusion criteria for Parkinson's disease</p> <p>History of:</p> <ul style="list-style-type: none">• repeated strokes with stepwise progression of parkinsonian features• repeated head injury• definite encephalitis• oculogyric crises• neuroleptic treatment at onset of symptoms• more than one affected relative• sustained remission• strictly unilateral features after 3 years• supranuclear gaze palsy• cerebellar signs• early severe autonomic involvement• early severe dementia with disturbances of memory, language, and praxis• Babinski sign• presence of cerebral tumor or communication hydrocephalus on imaging study• negative response to large doses of L-DOPA in absence of malabsorption• MPTP exposure
<p>Step 3 - Supportive prospective positive criteria for Parkinson's disease</p> <p>Three or more required for diagnosis of definite PD, in combination with step one:</p> <ul style="list-style-type: none">• unilateral onset• rest tremor present• progressive disorder• persistent asymmetry affecting side of onset most• excellent response (70-100%) to L-DOPA• severe L-DOPA-induced chorea• L-DOPA response for 5 years or more• clinical course of ten years or more

Figure 2 - United Kingdom Parkinson's Disease Society Brain Bank Criteria for PD diagnosis (8).

<p>1,0: Unilateral involvement only</p> <p>1,5: Unilateral and axial involvement</p> <p>2,0: Bilateral involvement without impairment of balance</p> <p>2,5: Mild bilateral disease with recovery on pull test</p> <p>3,0: Mild to moderate bilateral disease; some postural instability; physically independent</p> <p>4,0: Severe disability; still able to walk or stand unassisted</p> <p>5,0: Wheelchair bound or bedridden unless aided</p>

Figure 3 - Modified Hoehn & Yahr staging scale (mH&Yss) (23).

2.2. Controls

The HC group had 32 participants, 19 males (59,4%) and 13 females (40,6%), with age between 55 and 86 years. They were all volunteers from CHCB. Most of them were recruited from Urology and Gynecology sectors.

All volunteers underwent an interview with a questionnaire (Annex 2), neurological and physical exam, laboratory tests and medical records evaluation. A summary neurological examination was performed⁶ to exclude neurological symptoms and cardiac and pulmonary evaluations provided additional clinical information. Interview and medical record evaluation allowed to obtain comorbidities and actual medications.

All documents were identified by study number to maintain confidentiality.

2.3. Ethical Approval

Patients and HC had given their informed consent to the study (Annex 3). The research protocol was approved by the Ethical Committee of CHCB.

2.4. Exclusion Criteria

The exclusion criteria for PD patients are those included in UKPDBBC.

HC taking the following medications were excluded: urate synthesis inhibitors; anticoagulants; antiplatelets; vitamin supplements (except D vitamin supplements); PPAR γ agonists (glitazones); serotonin-noradrenaline reuptake inhibitors; β 2-agonists; antipsychotics; dopamine antagonists and agonists; catechol-O-methyl transferase (COMT) inhibitors; Monoamine oxidase (MAO) inhibitors; N-methyl-D-aspartate (NMDA) inhibitors; and acetylcholine agonists and antagonists. Likewise, active smokers, individuals with personal history of secondary parkinsonism, neurodegenerative diseases, stroke or chronic kidney disease (CKD), and those with head injury, myocardial infarction or surgery in the last three months were also excluded from HC group.

We also excluded the patients and controls with inflammatory and immune diseases⁷, acute or chronic infectious disease, hepatic failure, alcohol addiction, myocardial infarction and surgery within the last 6 months and actual treatment with non-steroids anti-inflammatory drugs (NSAIDs), glucocorticoids [except intranasal⁸ (25)], immunosuppressors, systemic

⁶ We evaluated the following. Cranial nerves number II (visual fields); III, IV and VI (ocular motility); VII-motor (wrinkle forehead, close eyes tight, show teeth); and XII (stick out tongue and move it side to side). Tremor (patient's arms are held outstretched and fingers extended), hand rapid alternating movements (finger tapping), finger-to-nose, muscular tone (elbow, wrist and knee passive movements), diadochokinesia (alternating pronate and supinate movements), osteotendinous reflexes (biceps, finger flexors and patellar) and plantar reflex.

⁷ Except one of the controls, who has Myasthenia Gravis, but inflammatory markers were normal.

⁸ Systemic bioavailability less than 2%.

hormonal therapy (except nonsteroidal), antibiotics, and cytostatics⁹. Those who had estimate glomerular filtrate rate (eGFR) < 60 mL/min/1.73m² during more than one year were also excluded; e-GFR was calculated through Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation¹⁰.

2.5. Sample collection

Venipuncture was performed in the morning and immediately after the clinical evaluations, without fasting. The responsible physician prescribed routine analysis and, at the same time, we collected peripheral blood samples to a tube without anticoagulant. Within an hour, that tube was transported to Clinical Pathology Laboratory of CHCB where it was centrifuged and kept at 4 degrees. Within 5 hours the tube was transported to the Health Science Research Center (CICS) at the Universidade da Beira Interior where the serum was divided in micro-tubes and stored at -70°C.

In our study, we used some of the values from routine analyses prescribed by the responsible physician. Peripheral blood samples were collected to one tube without anticoagulant and to one ethylenediamine tetraacetic acid (EDTA) tube. Within an hour, the tubes were transported and they were immediately analyzed in Clinical Pathology Laboratory of CHCB.

2.6. Sample analysis

The sample analysis included cytokines measurement, CRP, ESR, serum creatinine (Cr), leukogram, urate and hemogram (Table 1).

One of the micro-tubes of serum was used in the cytometric bead array analysis - BD™ CBA Human Inflammatory Cytokines Kit (BDCBAHICK), which allows the measurement of IL-8, IL-18, IL-6, IL-10, TNF, and IL-12p70 protein levels in a single sample, using beads of known size and fluorescence. Each capture bead has been conjugated with a specific antibody, enabling the detection of a set of analytes using flow cytometry.

The entire procedure is explained in Annex 4. All collected samples were analyzed in the same day.

⁹ Except one of the PD patients, who was using hydroxyurea to Policitemia Vera.

¹⁰ eGFR = 141 X min(Cr/κ,1)^α X max (Cr/κ,1)^{-1.209} X 0.993^{Age} X 1.018 [if female] X 1.159 [if black], where Cr is serum creatinine (mg/dL), κ is 0.7 for females and 0.9 for males, α is -0.329 for females and -0.411 for males, min indicates the minimum of Cr/κ or 1, and max indicates the maximum of Cr/κ or 1.

Table 1 - Sample analysis performed. BD™ CBA Human Inflammatory Cytokines Kit (BDCBAHICK).
(a) Performed at Clinical Pathology Laboratory of CHCB. (b) Performed at CICS laboratory.

Tube	Values to determinate	Objective	Method
Without anticoagulant	Cr ^(a)	Renal function	Kinetic colorimetric assay based on Jaffé method
	Urate ^(a)	Antioxidant	Enzymatic colorimetric assay
	CRP ^(a)	Inflammatory status	Immunoturbidimetry
	Cytokines ^(b)		BDCBAHICK
EDTA	ESR ^(a)		Modified Westergren method
	Hemogram ^(a)	Immunological status	Cytometry

2.7. Statistical analysis

The variables studied are present in Table 2.

In order to explore the disease variables, PD patients were divided:

- Into 2 subgroups according with mH&Yss: Early Stage (mH&Yss < 2,0) and Late Stage (mH&Yss ≥ 2,0) - Disease Stage subgroups;
- Into 3 subgroups according with disease duration: Short Duration (< 5 years), Middle Duration ([5-10[years), and Long Duration (≥ 10 years) - Disease Duration subgroups;
- Into 2 subgroups according with immediate release L-DOPA¹¹ (26) dose: Low Dose (<300 mg/day) and High Dose (≥300 mg/day) - L-DOPA Dose subgroups.

¹¹ Extended release (ER) L-DOPA was converted for immediate release (IR). Conversion from ER to IR is the following: 200mg ER = 350 mg/day IR; 300 mg ER 12h/12h or 200 mg ER 8h/8h = 550 mg/day IR; 800 mg ER 8h/8h = 750 mg/day IR; 1000 ER 8/8h = 950 mg/day IR (26).

Table 2 - Variables investigated.

Patients and Controls			Patients		
Demographic	Age		Disease variables	Age at onset	
	Gender			Disease severity	mH&Yss
Inflammatory parameters	Cytokines				Disease duration
	Biochemical parameters	C reactive protein (CRP)		Immediate release L-DOPA dose	
		Erythrocyte sedimentation rate (ESR)		Symptoms at onset	
Symptoms at evaluation					
Renal function	Estimate glomerular filtrate rate (eGFR)				
Leukogram	Leucocytes [absolute count (AC)]				
	Neutrophils (AC)				
	Lymphocytes (AC)				
	Monocytes (AC)				
	Eosinophils (AC)				
	Basophiles (AC)				
Oxidative parameters	Urate				
Hemogram	Hemoglobin (Hb)				
	Mean corpuscular volume (MCV)				
	Mean corpuscular hemoglobin concentration (MCHC)				
	Red Cell Distribution Width (RDW)				
Medical history					

2.8. Data Analysis

Normal distribution was assessed with Shapiro-Wilk test. Differences in study variables between PD and HC groups were assessed by analysis of variance, unpaired T-test and Mann-Whitney U test for continuous measures, and Chi-square test was used for categorical variables. Correlation was used to assess the relationship between variables.

A *p* value of less than 0.05 was regarded as statistically significant.

Data are presented as means \pm standard deviation for continuous measures and percentages and counts (in parenthesis) for categorical variables.

Statistical analysis was performed using GraphPad Prism version 5 and IBM SPSS Statistics version 20.

3. Results

3.1. Patient recruitment

Patients were recruited from appointment list of CHCB Neurology sector, between January 2013 and December 2013. 39 patients were identified with PD diagnosis established by the UKPDBBC (8) 35 potential HC were identified according with the previous criteria. In the appointment day, we proceed with clinical evaluation and blood sample collection. At the end of the study 38 patients and 32 HC were validated (one patient was excluded because the blood sample was not collected and three HC were excluded because they presented stage 3 CKD). None of the patients presented 5 on mH&Yss.

3.2. Demographic characteristics of study population

We start by analyzing the demographic characteristics of study population. PD and HC groups are similar in gender distribution. However, PD group, mainly women, is older than HC group. (Tables 3 and 4)

Table 3 - Gender distribution of study population. Male (M). Female (F).
^a Chi-square test.

Gender	PD group (n=38)	HC group (n=32)	p value
M	55.25% (21)	59.38% (19)	0.729 ^a
F	44.74% (17)	40.63% (13)	

Table 4 - Age distributions of study population.
^b Mann-Whitney U test; ^c T-test.

	Gender	PD group (n=38)	HC group (n=32)	p value
Mean age (years)	M	72.52 ± 6.71 (21)	68.16 ± 10.09 (19)	0.259 ^b
	F	75.35 ± 7.25 (17)	66.00 ± 9.55 (13)	0.005 ^c
	M/F	73.79 ± 7.00 (38)	67.28 ± 9.78 (32)	0.007 ^b

3.3. Clinical characteristics of PD patients

To further investigation of our patients, we analyzed their clinical characteristics, focusing on medical history and symptomatology (Tables 5 and 6; Graphs 1-3). All PD participants present comorbidities, being HTA the most prevalent (Table 5).

Table 5 - PD group medical history, with main comorbidities represented.

Comorbidities	PD group (n=38)
HTA	65.79% (25)
Musculoskeletal/ rheumatologic problems	36.84% (14)
Type 2 DM	28.95% (11)
Hyperlipidemia	18.42% (7)
Profound venous thrombosis/ Venous insufficiency	13.16% (5)
Hypothyroidism (on treatment)	10.53% (4)
Stroke/ Transitory ischemic accident history	10.53% (4)
Congestive heart failure	10.53% (4)
Benign prostatic hyperplasia	10.53% (4)
Obstructive sleep apnea	10.53% (4)
No comorbidities	0% (0)


Table 6 - Clinical features of PD patients. Positive familiar history is considered positive when patients have at least 2 relatives with PD.

	Patients (n=38)
Mean age at PD onset (years)	66.86 ± 8.21
Mean PD duration (years)	6.93 ± 4.24
Mean stage in mH&Yss	1.90 ± 1.00
Mean dose of L-DOPA (mg/day) ¹²	430.20 ± 220.70
Positive familiar history	2.63% (1)


Symptoms at onset and at evaluation were accessed, in order to compare the progression of the disease symptomatology. The majority of patients presented tremor as initial symptom. Two of them presented a non motor symptom: widespread pain and paresthesia in the right arm. (Graph 1)

At evaluation, rigidity was the most frequent symptom (Graph 2).

¹² Three PD patients were not taking L-DOPA at evaluation day.




Graph 1 - Cardinal symptoms at onset. The variable “Other” represents the PD patients with non motor symptoms.



Graph 2 - Cardinal symptoms at evaluation

We determinate the mH&Yss at evaluation and most patients present early stage disease (mH&Yss < 2,0) (Graph 3).



Graph 3 - mH&Yss distribution of PD patients. Each color represents a stage of mH&Yss of PD population.

Patients with a more prolonged disease presented higher mH&Yss value and they take the higher doses of L-DOPA.

Patients on late stage, taking lower doses of L-DOPA, presented more tremor at evaluation than those taking higher doses. However, this is not observed for others symptoms.

3.4. Inflammatory parameters

In order to explore the inflammatory side of PD, we evaluated the serum concentration of cytokines that were previously proposed to be associated with the disease. Besides, we analyzed the values of unspecific systemic inflammatory markers routinely used in clinic (CRP and ESR).

3.4.1. Cytokine measurement with BDCBAHICK

In the 38 PD patients and 32 HC, all cytokines measured (IL-8, IL-18, IL-6, IL-10, TNF, and IL-12p70) are below the lower limits of detection (LLOD) (see Table 7).

Table 7 - Lowe limits of detection (LLOD) for each cytokine, according with BDCBAHICK Instruction Manual.

Cytokine	LLOD (pg/mL)
IL-12p70	2,5
TNF	3,0
IL-10	3,0
IL-6	3,9
IL-1B	2,9
IL-8	5,4

In Annex 5, the fluorescence intensity (FI) presented by each sample is displayed. The median and standard deviation of FI are presented on Table 8.

Table 8 - Median FI obtained for PD and HC groups. All cytokines measured were below the LLOD.

Cytokine	PD		HC	
	Median FI	Standard deviation	Median FI	Standard deviation
IL-12p70	1.65	0.06	1.62	0.04
TNF- α	2.08	0.04	2.09	0.03
IL-10	2.15	0.05	2.15	0.05
IL-6	2.75	0.06	2.76	0.06
IL-1B	2.11	0.03	2.10	0.04
IL-8	4.50	0.08	4.57	0.09

The calibration curves for each cytokine are presented on Annex 6.

3.4.2. Biochemical parameters

CRP and ESR values for patients and controls are presented on Table 9. CRP is higher in PD patients.

Table 9 - Inflammatory parameters of PD and HC groups. For the variables that depend on gender values for males and females are presented. Due to errors in blood analysis requisition, verified at the time of the sample collection, some parameters were not analyzed in all the patients. For CRP and ESR analysis, we excluded patients on actual treatment with NSAIDs, glucocorticoids (except intranasal) and immunosuppressors. Normal ranges are on Annex 7. Male (M). Female (F).

^b Mann-Whitney U test; ^c T-test.


	Gender	Patients (n=38)	Controls (n=32)	p value
CRP (mg/dL)	M/F	0,30 \pm 0,17 (21)	0,26 \pm 0,17 (26)	0.050 ^c
ESR (mm/H)	M	8.67 \pm 6.93 (14)	8.24 \pm 5.13 (17)	0.970 ^b
	F	27.14 \pm 17.93 (7)	14.64 \pm 8.49 (11)	0.126 ^b

All inflammatory parameters are within the reference values for both groups (see Annex 7). For CRP and ESR measurements, participants with eGFR <60 mL/min/1.73m² on evaluation day were not included (Table 10).

Table 10 - eGFR of PD and HC groups, according with gender. Due to errors in blood analysis requisition, verified at the time of the sample collection, some parameters were not analyzed in all the patients. Male (M). Female (F).
^c T-test.

	Gender	Patients (n=38)	Controls (n=32)	p value
eGFR (mL/min/1.73m ²)	M	82.17 ± 19.17 (19)	83.01 ± 12.01 (19)	0.872 ^c
	F	62.78 ± 25.82 (17)	84.55 ± 13.01 (13)	0.010 ^c

eGFR is within the normal range for both groups (see Annex 7). Although there are no significant differences in the values obtained for the male groups, the PD female patients present eGFR levels significantly lower than females in the HC group (Graph 4).



Graph 4 - eGFR from PD and HC groups: females (a) and males (b) - scatter plot graphs. The biochemical parameters of inflammation scatter plot graphs for both groups are on Annex 8.

3.5. Leukogram parameters


We considered leukogram parameters so that we can have an overview of the study population immune status. The values for both PD and HC groups are presented on Table 11.

Table 11 - Leukogram parameters of PD and HC groups. Due to errors in blood analysis requisition, verified at the time of the sample collection, some parameters were not analyzed in all the patients. Normal ranges are on Annex 7. Male (M). Female (F).

^b Mann-Whitney U test; ^c T-test.

	Gender	Patients (n=38)	Controls (n=32)	p value
Leucocytes (10 ³ /uL)	M/F	6.89 ± 2.06 (37)	6.47 ± 1.70 (32)	0.250 ^c
Neutrophils (10 ³ /uL)	M/F	4.53 ± 1.56 (37)	3.96 ± 1.87 (32)	0.042 ^b
Lymphocytes (10 ³ /uL)	M/F	1.60 ± 0.59 (37)	1.83 ± 0.56 (32)	0.103 ^c
Monocytes (10 ³ /uL)	M/F	0.58 ± 0.19 (36)	0.50 ± 0.16 (32)	0.136 ^b
Eosinophils (10 ³ /uL)	M/F	0.13 ± 0.12 (37)	0.13 ± 0.15 (32)	0.913 ^b
Basophiles (10 ³ /uL)	M/F	0.04 ± 0.06 (37)	0.03 ± 0.05 (32)	0.681 ^b

All values are within the reference values for both groups (see Annex 7). We found that PD patients have higher values of neutrophils, comparing with HC (Graph 5).



Graph 5 - Neutrophils from PD and HC groups - scatter plot graphs. The remain leukogram parameters scatter plot graphs for both groups are on Annex 8.

The data obtained suggest a decrease in the number of lymphocytes throughout the temporal evolution of the disease (Table 12) and in patients using higher doses of L-DOPA (Table 13).

Table 12 - Analysis of lymphocyte number in patients, according with Disease Duration.
^d ANOVA test.

Disease Duration subgroups	Lymphocytes (10 ³ /uL)	p value	
Short Duration	1.64 ± 0.43 (12)	0.408 ^d	0.006 ^d
Middle Duration	1.92 ± 0.57 (12)		
Long Duration	1.21 ± 0.57 (12)		

Table 13 - Analysis of lymphocyte number in patients, according with L-DOPA Dose.
^b Mann-Whitney U test.

L-DOPA Dose subgroups	Lymphocytes (10 ³ /uL)	p value
Low Dose	1.83 ± 0,51 (21)	0.008 ^b
High Dose	1.30 ± 0,57 (16)	

Since usually patients with a more prolonged disease require higher doses of L-DOPA, in an attempt to clarify if the decrease of lymphocytes during the disease course was a consequence of the disease itself or a secondary effect of L-DOPA use, we analyzed the relationship between lymphocyte number and disease duration for different L-DOPA Dose subgroups. Although there is a tendency to observe a lower number of lymphocytes for higher doses of L-DOPA in all the groups, the difference was not statistically significant. (Table 14)

Table 14 - Crossed Disease Duration and L-DOPA Dose subgroups: comparison between L-DOPA Dose subgroups lymphocytes, according to disease duration.
^b Mann-Whitney U test.

Disease Duration subgroups	L-DOPA Dose subgroups	Lymphocytes (10 ³ /uL)	p value
Short duration	Low dose	1.74 ± 0.42 (9)	0.209 ^b
	High dose	1.33 ± 0.35 (3)	
Middle duration	Low dose	2.04 ± 0.61 (8)	0.435 ^b
	High dose	1.72 ± 0.48 (5)	
Long duration	Low dose	1.56 ± 0.42 (4)	0.109 ^b
	High dose	1.03 ± 0.57 (8)	

3.6. Oxidative parameters

Urate is a natural antioxidant proposed as a physiological indicator of the oxidative status. The data obtained show that PD urate levels are lower than the levels in the HC group, especially for male population (Table 15). This decrease is even more pronounced for the patients within higher stages of the disease (Table 16) and higher disease duration (Table 17). In what concerns the female population, the tendency to lower urate values in the PD group is obtained mainly in patients with longer disease (Tables 15-17).

Table 15 - Urate values of PD and HC groups, according with gender. Due to errors in blood analysis requisition, verified at the time of the sample collection, some parameters were not analyzed in all the patients. Normal ranges are on Annex 7. Male (M). Female (F).

^c T-test.

	Gender	Patients (n=38)	Controls (n=32)	p value
Urate (mg/dL)	M	5.08 ± 1.22 (15)	5.99 ± 1.27 (18)	0.045 ^c
	F	4.17 ± 1.05 (8)	4.61 ± 0.96 (13)	0.345 ^c

Table 16 - Comparison between urate levels of male and females from PD group, according with Disease Stage. Male (M). Female (F).

^c T-test.

Gender	Disease Stage subgroups	Urate (mg/ dL)	p value
M	Early stage	5.78 ± 0.80 (8)	0.012 ^c
	Late stage	4.29 ± 1.17 (2)	
F	Early stage	4.40 ± 0.14 (4)	0.584 ^c
	Late stage	3.95 ± 1.34 (2)	

Table 17 - Comparison between urate levels of male and females from PD group, according with Disease Duration. Male (M). Female (F).

^d ANOVA test.

Gender	Disease Duration subgroups	Urate (mg/ dL)	p value
M	Short Duration	5.10 ± 1.30 (5)	0.956 ^d
	Middle duration	5.35 ± 1.17 (4)	
	Long Duration	4.88 ± 1.33 (6)	0.846 ^d
F	Short Duration	5.15 ± 0.07 (2)	0.578 ^d
	Middle Duration	4.63 ± 0.38 (3)	
	Long Duration	3.07 ± 0.76 (3)	0.036 ^d

Although PD patients exhibit slightly lower values of urate than HC, there is no significant difference of urate values between HC and PD patients with the less severe disease (Early Stage and Short Duration subgroups; Table 18).

Table 18 - Comparison between urate levels of male and females from Early Stage PD subgroup and HC group. Male (M). Female (F).

^c T-test.

PD group			HC group	p value
Gender	Disease Stage subgroups	Urate (mg/ dL)	Urate (mg/ dL)	
M	Early stage	5.78 ± 0.80 (8)	5.99 ± 1.27 (18)	0.665 ^c
	Short Duration	5.10 ± 1.30 (5)		0.181 ^c
F	Early stage	4.40 ± 0.14 (4)	4.61 ± 0.96 (13)	0.702 ^c
	Short Duration	5.15 ± 0.07 (2)		0.068 ^c

3.7. Hemogram parameters


To further characterize the study population, we analyzed the hemogram parameters (Table 19).

Table 19 - Hemogram parameters of PD and HC groups. For the variables that depend on gender values for males and females are presented. Due to errors in blood analysis requisition, verified at the time of the sample collection, some parameters were not analyzed in all the patients. Normal ranges are presented on Annex 7. Male (M). Female (F).

^b Mann-Whitney U test; ^c T-test.

	Gender	Patients (n=38)	Controls (n=32)	p value
Hb (g/dL)	M	14.06 ± 1.51 (20)	14.59 ± 1.13 (19)	0.220 ^c
	F	12.39 ± 1.12 (17)	13.37 ± 0.88 (13)	0.015 ^c
MCV (fL)	M/F	92.60 ± 8,53 (37)	91.85 ± 6.33 (32)	0.754 ^b
MCHC (g/dL)	M/F	33.58 ± 8.82 (37)	34.39 ± 2.56 (32)	0.067 ^b
RDW (%)	M/F	14.35 ± 3.48 (37)	13.56 ± 1.10 (32)	0.250 ^b

All values are within the reference values for both groups (Annex 7). The results obtained show that hemoglobin (Hb) levels from PD are lower than the levels in HC, mainly in females (Graph 6).



Graph 6 - Hb from PD and HC groups: females (a) and males (b) - scatter plot graphs. The remain hemogram parameters scatter plot graphs for both groups are on Annex 8.

4. Discussion

PD is a neurodegenerative disease, affecting more the male population (27) and people over 60 years old, with mean age at diagnosis approximately 70.5 years (28).

The PD population of our study was also composed mostly by men, with mean age at disease onset of 73.8 years. It can be considered representative of the PD population, because it has demographic characteristics similar to those of epidemiologic studies, with an earlier onset of the disease of approximately 4 years. HC group has an equal gender distribution and it is younger than the PD group (Tables 3 and 4). The age difference is probably explained by the fact that HC male population was mostly recruited from Urology sector, in which men population is usually old, and HC female population was mostly recruited from Gynecology sectors, in which women population is usually young.

Comparing medical history, PD group has more comorbidities associated (Table 5), probably because it is an older population and/or because their health status is better characterized due to its high medical surveillance (they have regular Neurology appointments).

The diagnosis of PD, accordingly with NICE current guidelines (7), is established through UKPDSBBC, with the presence of bradykinesia and at least one of the other cardinal symptoms (rigidity, rest tremor and postural instability) (8). In what concern the symptoms, tremor is the most frequent, followed by rigidity (22). Postural instability is the last one to appear, resulting from an impairment of centrally mediated postural reflexes (3).

PD patients of our study had an onset symptomatology similar to those described in literature, with tremor being the most common symptom (84.21%; Graph 1). Rigidity was the second most common, present in 10.53% of cases (Graph 1). However, at evaluation rigidity became the most frequent symptom (81.58%; Graph 2). This could be explained by the fact that tremor is probably the symptom more visible to the observer and the one with the highest improvement with treatment, so it is highlighted at onset and then patients experience a real decrease in tremor.

As expected, none of the patients presented postural instability as onset symptom, but at evaluation, it emerges on 4 patients (10.53%), with disease duration ≥ 10 years (Graph 2).

We noticed that patients within Late Stage ($mH\&Yss \geq 2$) or Long Duration disease (disease duration ≥ 10 years), who took a low dose of L-DOPA (<300 mg/day) presented more tremor at evaluation. We can assume that, for those patients, tremor could be controlled by increasing L-DOPA dose. Tremor was also the symptom with the highest improvement, which could explain the decreased number of patients with tremor on evaluation.

Physiopathology underlying the DN degeneration are still not completely understood, however several studies proved that neuroinflammation plays a central role on PD physiopathology, due to microglia chronic activation (10, 17). Activated microglia synthesize inflammatory markers, including cytokines, which through autocrine signalling create a self-propagating cycle of microglia activation. (9, 12) Several studies shown significantly higher levels of cytokines in serum and CSF of PD patients when compared with HC,(9) including pro-inflammatory cytokines, like IL-6 (12, 17), IL-12 (19), TNF- α , (12, 18) and interferon- γ (12), and anti-inflammatory cytokines, namely IL-2, IL-4 (12) and IL-10 (12, 19). There are also evidences of slightly higher levels of pro-inflammatory (IL-1 β , IL-6, IL-8 and IL-12) (18, 19) and anti-inflammatory (IL-10) (18) cytokines in PD patients' serum, without statistical significance. The studies with a similar method of sample collection, storage and cytokine measurement [Cytometric Bead Array (CBA)] (12, 18) presented results not consistent. Koziorowski et al.(18) obtained cytokine values with a much lower magnitude order and TNF- α and IL-6 were undetectable for HC. Two of those studies (12, 18) shown detectable values of the others cytokines in HC.

Extending our literature search to other areas, researches with CBA method have inconsistent results too. Several studies detected IL-10, IL-12p70 and IL-6 values bellow our LLOD. (29, 30) Although, it is described that cytokine levels in plasma are higher than in serum (30).

In order to approach this neuroinflammatory side of PD, we proposed to evaluate serum concentration of IL-1 β , IL-8, IL-6, IL-10, TNF, and IL-12p70 in PD patients and HC and to compare the cytokine pattern between those two groups. Contrary to what we expected, all cytokines were below the LLOD for both PD and HC groups. The serum samples were kept refrigerated within 5 hours at maximum, before being stored at -80°C, thus strongly limiting sample degradation. CBA assay method has advantages over conventional ELISA methodology. It measures the concentration of an unknown analyte in less time and using fewer sample dilutions, because of the broad dynamic range of fluorescent detection via flow cytometry and the efficient capturing of analytes via suspended particles. Our methodology was accurate, because we obtained linear calibration curves, as we can see on Annex 6. However, the assay has limitations. The theoretical limit of detection of BDCBAHICK is comparable to conventional ELISA, but the actual limit of detection in a given experiment may vary slightly due to the complexity and kinetics of this multi-analyte assay. It could be interesting to repeat the cytokines measurement on plasma instead of serum and simultaneously increase the study population.

In order to complement our research about inflammation in PD, we also analyze unspecific systemic inflammatory markers routinely used in clinic, namely CRP and ESR (Table 9). CRP was higher in PD patients, but still much low than the reference value. We did not find differences between ESR values, however male from PD population presented lower values, which stands against the findings on CRP. We have to emphasize that we collected a lower number of sample for ESR measurement, so to further conclusions we should could increase the number of samples.

Still, there is doubt about the truly origin of increased cytokines in the PD patients serum. It might involve the efflux of cytokines from the CNS through the blood brain barrier (12), which presents a higher permeability in PD patients (31). However, immune activation in PD is not restricted to CNS (17) and peripheral activated lymphocytes could produce the cytokines, which is explained by a relationship between lymphocyte number and the elevation of serum cytokines (12). There are also changes in subpopulations of blood lymphocytes, with reduced levels of T helper and B lymphocytes (32). In addition, there are evidences of higher levels of leukocytes in PD patients than in HC (12).

To explore those facts, we analyse leukogram of study population. At first sight, we detect a higher level of neutrophils in PD population (Table 11). Regarding lymphocytes, in PD patients their value decreases with progression of disease duration and elevation of L-DOPA dose. This leads us to a question: the decrease of lymphocytes values results from temporal evolution of disease or it is an adverse effect from L-DOPA. Considering the disease physiopathology is possible to assume that changes in immune system will become severe with temporal disease progression. It is not described any L-DOPA adverse effect related with lymphocytes levels. In order to explore this question, we divided PD patients into subgroups according with disease stage, disease duration and L-DOPA dose and we compare lymphocyte levels between those subgroups. We found that patients with Long Duration disease and High Doses of L-DOPA presented significantly lower values of lymphocytes (Table 12 and 13). As patients with a more prolonged disease usually use higher doses of L-DOPA, we analyzed the relationship between lymphocyte number and disease duration for different L-DOPA dose subgroups. There is a tendency to observe a lower number of lymphocytes for higher doses of L-DOPA in all the groups, but it is not statistically significant (Table 14). Then, we can not take conclusions about the truly cause of lymphocytes variations in PD patients. It would be interesting to do a differential analysis of PD patients' lymphocytes, in order to assess which phenotype has the greater variance. The duration of L-DOPA treatment could also give us interesting results.

Exploring another aspect, oxidative stress can also play a key role on PD physiopathology and antioxidants may be an endogenous defence against the disease (13). Urate, the end product of purine metabolism, it is a potent antioxidant, peroxynitrite scavenger, iron chelator, and ascorbate stabilizer (31, 33). Evidences suggest that high blood and CSF urate concentrations are related with a reduced risk of PD (31, 33) and with a decreases disease progression rate, including cognitive decline (33). This inverse association was independent from age, smoking, caffeine consumption, and other aspects of lifestyle that have been related to both PD and uraemia (31). Those data could establish urate as the first molecular predictor of clinical progression in PD (33). However, there is still not sufficient data to support a recommendation for urate increase as therapeutic measure (31, 33).

As expected, urate presented lower values on PD group, especially on male population (Table 15). Our urate values for PD patients are consistent with other studies (31, 33). Late Stage

and Long Duration PD patients presented lower values, again specially on male population (Table 16 and 17). In order to understand if urate could be a marker of PD initial phase, we compare Early Stage and Short Duration PD patients with HC group. We detect that male population had slightly lower values of urate, as expected. However, female population present the inverse. (Table 18). We must emphasize the fact that our study presents limitations at this level, because we only proceeded to a single measurement of urate and we did not control confounding factors related to lifestyle. Medical records review and repeated urate measurements for PD patients will probably give us interesting results. However, we can assume that urate could be a putative marker of disease severity, at least on male population. Our data are promising and increasing the number of the study population, we could probably corroborate our findings.

Additional information about oxidative stress could be obtain through the measurement of an oxidative stress marker on peripheral blood, such as 8-hydroxyguanosine, which results from nucleoside oxidation, since recent studies shown high levels of these substances in PD peripheral blood (34).

Besides PD etiology remains largely unknown (1, 2, 9), some risk factors have been already described. Anemia is one of them, with slightly but consistently lower levels of Hb during life, when compared with controls (35). On the other hand, smoking and vitamin E¹³ are associated with a lower risk of developing PD (1).

In our study, PD patients presented lower Hb values, especially female participants, but still with no anemia criteria (Table 19 and Annex 7). However we can not interpret these results, because PD females are older and confounding factors were not eliminated [such as cigarette smoking, exposure to pesticides, or hysterectomy (35)].

Looking towards our work, we can point some limitations. First, the small sample size and single-point measurements of serum cytokines and biochemical data limited our statistical power in the analyses. Second, PD group sample was older than HC, making difficult to compare and to take conclusions about some of the variables. Third, mH&Yss and disease duration are rough methods to describe disease progression. For last, we included a large number of variables, making impossible to control the confounding factors for each one of them.

Nevertheless, we used medical record of study participants, making possible to analyze with certainty the disease variables for PD patients; confounding factors for cytokines analysis were eliminated (see Material and Methods - Exclusion criteria); and exclusion criteria were much more restrictive for HC group, whereby our sample is representative of a healthy population with the age and gender distribution described.

¹³ Only in some case-controls studies; prospective studies did not confirm that finding.

In summary, we can highlight the following points. In concern of characterization of PD population of CHCB, it is an elderly population, with mean age of 73.8 years, mainly composed by men. Regarding inflammatory aspects of the disease, our study showed that cytokine pattern is not sensitive or specific to assess disease progression, because results are very inconsistent. However, our results are in favor of the involvement of immune system and probably a deeper investigation could bring us more information about temporal disease progression and a way to better characterize the disease. On the other hand, antioxidant urate presents us as a putative biomarker of disease severity.

This study is only a starting point. It allowed us characterize PD population of the region and start a research that, in the future, should be divided in order to better describe each of the issues addressed. Furthermore, more subjects should be included in both groups, with the aim of collecting the necessary information to extrapolate our results with confidence.

References

1. de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. *Lancet neurology*. 2006;5(6):525-35. Epub 2006/05/23.
2. Toulouse A, Sullivan AM. Progress in Parkinson's disease-where do we stand? *Progress in neurobiology*. 2008;85(4):376-92. Epub 2008/06/28.
3. Langston JW. The Parkinson's complex: parkinsonism is just the tip of the iceberg. *Annals of neurology*. 2006;59(4):591-6. Epub 2006/03/28.
4. Wu Y, Le W, Jankovic J. Preclinical biomarkers of Parkinson disease. *Archives of neurology*. 2011;68(1):22-30. Epub 2011/01/12.
5. Siderowf A, Stern MB. Preclinical diagnosis of Parkinson's disease: are we there yet? *Current neurology and neuroscience reports*. 2006;6(4):295-301. Epub 2006/07/11.
6. Savica R, Rocca WA, Ahlskog JE. When does Parkinson disease start? *Archives of neurology*. 2010;67(7):798-801. Epub 2010/07/14.
7. Parkinson's Disease: National clinical guideline for diagnosis and management in primary and secondary care. London 2006.
8. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. *Journal of neurology, neurosurgery, and psychiatry*. 1992;55(3):181-4. Epub 1992/03/01.
9. Collins LM, Toulouse A, Connor TJ, Nolan YM. Contributions of central and systemic inflammation to the pathophysiology of Parkinson's disease. *Neuropharmacology*. 2012;62(7):2154-68. Epub 2012/03/01.
10. Vila M, Przedborski S. Genetic clues to the pathogenesis of Parkinson's disease. *Nature medicine*. 2004;10 Suppl:S58-62. Epub 2004/07/24.
11. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. *Neurobiology of aging*. 2003;24(2):197-211. Epub 2002/12/25.
12. Brodacki B, Staszewski J, Toczyłowska B, Kozłowska E, Drela N, Chalimoniuk M, et al. Serum interleukin (IL-2, IL-10, IL-6, IL-4), TNFalpha, and INFgamma concentrations are elevated in patients with atypical and idiopathic parkinsonism. *Neuroscience letters*. 2008;441(2):158-62. Epub 2008/06/28.
13. Jenner P. Oxidative stress in Parkinson's disease. *Annals of neurology*. 2003;53 Suppl 3:S26-36; discussion S-8. Epub 2003/04/01.
14. Liu B, Hong JS. Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. *The Journal of pharmacology and experimental therapeutics*. 2003;304(1):1-7. Epub 2002/12/20.

15. Zhang J, Perry G, Smith MA, Robertson D, Olson SJ, Graham DG, et al. Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. *The American journal of pathology*. 1999;154(5):1423-9. Epub 1999/05/18.
16. McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. *Neurology*. 1988;38(8):1285-91. Epub 1988/08/01.
17. Chen H, O'Reilly EJ, Schwarzschild MA, Ascherio A. Peripheral inflammatory biomarkers and risk of Parkinson's disease. *American journal of epidemiology*. 2008;167(1):90-5. Epub 2007/09/25.
18. Kozirowski D, Tomasiuk R, Szlufik S, Friedman A. Inflammatory cytokines and NT-proCNP in Parkinson's disease patients. *Cytokine*. 2012;60(3):762-6. Epub 2012/08/23.
19. Rentzos M, Nikolaou C, Andreadou E, Paraskevas GP, Rombos A, Zoga M, et al. Circulating interleukin-10 and interleukin-12 in Parkinson's disease. *Acta neurologica Scandinavica*. 2009;119(5):332-7. Epub 2008/11/04.
20. Zhang W, Wang T, Pei Z, Miller DS, Wu X, Block ML, et al. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*. 2005;19(6):533-42. Epub 2005/03/26.
21. Nyhlen J, Constantinescu R, Zetterberg H. Problems associated with fluid biomarkers for Parkinson's disease. *Biomarkers in medicine*. 2010;4(5):671-81. Epub 2010/10/16.
22. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. *Neurology*. 1967;17(5):427-42. Epub 1967/05/01.
23. Goetz CG, Poewe W, Rascol O, Sampaio C, Stebbins GT, Counsell C, et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. *Movement disorders : official journal of the Movement Disorder Society*. 2004;19(9):1020-8. Epub 2004/09/17.
24. Chou KL, Hurtig, H. I., Dashe, J. F. Clinical manifestations of Parkinson disease. 2012 May, 2013
25. Fluticasone intranasal (Rx). Medscape Reference2014 [cited 2014 18-04-2014]; Available from: <http://reference.medscape.com/drug/flonase-veramyst-fluticasone-intranasal-999637#10>.
26. Carbidopa/levodopa (Rx). Medscape Reference2014 [cited 2014 18-04-2014]; Available from: <http://reference.medscape.com/drug/sinemet-carbidopa-levodopa-343043#0>.
27. Tanner CM, Goldman SM. Epidemiology of Parkinson's disease. *Neurologic clinics*. 1996;14(2):317-35. Epub 1996/05/01.
28. Van Den Eeden SK, Tanner CM, Bernstein AL, Fross RD, Leimpeter A, Bloch DA, et al. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. *American journal of epidemiology*. 2003;157(11):1015-22. Epub 2003/06/05.

29. Sun X, Cao ZB, Zhang Y, Ishimi Y, Tabata I, Higuchi M. Association between serum 25-hydroxyvitamin D and inflammatory cytokines in healthy adults. *Nutrients*. 2014;6(1):221-30. Epub 2014/01/24.
30. Wong HL, Pfeiffer RM, Fears TR, Vermeulen R, Ji S, Rabkin CS. Reproducibility and correlations of multiplex cytokine levels in asymptomatic persons. *Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology*. 2008;17(12):3450-6. Epub 2008/12/10.
31. Weisskopf MG, O'Reilly E, Chen H, Schwarzschild MA, Ascherio A. Plasma urate and risk of Parkinson's disease. *American journal of epidemiology*. 2007;166(5):561-7. Epub 2007/06/23.
32. Stevens CH, Rowe D, Morel-Kopp MC, Orr C, Russell T, Ranola M, et al. Reduced T helper and B lymphocytes in Parkinson's disease. *Journal of neuroimmunology*. 2012;252(1-2):95-9. Epub 2012/08/23.
33. Ascherio A, LeWitt PA, Xu K, Eberly S, Watts A, Matson WR, et al. Urate as a predictor of the rate of clinical decline in Parkinson disease. *Archives of neurology*. 2009;66(12):1460-8. Epub 2009/10/14.
34. Chen CM, Liu JL, Wu YR, Chen YC, Cheng HS, Cheng ML, et al. Increased oxidative damage in peripheral blood correlates with severity of Parkinson's disease. *Neurobiology of disease*. 2009;33(3):429-35. Epub 2008/12/27.
35. Savica R, Grossardt BR, Carlin JM, Icen M, Bower JH, Ahlskog JE, et al. Anemia or low hemoglobin levels preceding Parkinson disease: a case-control study. *Neurology*. 2009;73(17):1381-7. Epub 2009/10/28.

Appendix

Annex 1 - Questionnaire applied to PD patients



CENTRO DE INVESTIGAÇÃO EM CIÊNCIAS DA SAÚDE
FACULDADE DE CIÊNCIAS DA SAÚDE, UNIVERSIDADE
DA BEIRA INTERIOR

**PROJECTO DE INVESTIGAÇÃO: IDENTIFICAÇÃO EM FLUIDOS BIOLÓGICOS DE
POSSÍVEIS BIOMARCADORES DE UMA FASE PRECOCE DA DOENÇA DE
PARKINSON**

Nº de Identificação (nº de processo): _____ Idade: _____ Género: _____ Data: ____/____/20____

Apenas para os doentes em que está estabelecido o diagnóstico de DP:

Grau da Escala Hoehn & Yahr Modificada: _____

Presença de alterações associadas à fase pré-motora:

Tremor ; Especificar lado em que iniciou:

Alterações de comportamento do sono REM
 Obstipação
 Depressão
 Outras; Especificar: _____

Há quanto tempo foi diagnosticada a doença: _____

Medicação anti-parkinsoniana actual:
.....
.....
.....

Medicação anti-parkinsoniana prévia:
.....
.....
.....

Outras Medicamentos Actuais:
.....
.....
.....
.....
.....
.....

Annex 2 - Questionnaire applied to healthy controls

 **CICS** CENTRO DE INVESTIGAÇÃO EM CIÊNCIAS DA SAÚDE
FACULDADE DE CIÊNCIAS DA SAÚDE, UNIVERSIDADE
DA BEIRA INTERIOR

**PROJECTO DE INVESTIGAÇÃO: IDENTIFICAÇÃO EM FLUIDOS BIOLÓGICOS DE
POSSÍVEIS BIOMARCADORES DE UMA FASE PRECOCE DA DOENÇA DE
PARKINSON**

Nº de Identificação: _____ ; Idade: _____ Género: _____

Medicação Actual:

- Anti-inflamatórios. Quais?
Quanto tempo desde a última toma?
- Imunossupressores. Quais?
- Terapia hormonal. Quais?
- Outros:
-
-

Outras patologias (especificar desde quando): **excluir de imediato se S. Parkinsoniano**

- Diabetes..... Síndrome demencial
- HTA História de AVC/ AIT
- Dislipidemias História de TCE repetidos; quando?
- Hipotireoidismo Doença coronária Cardíaca.....
- Doença aguda; especificar:
- Outras patologias crónicas; quais?

Hábitos:

- Atividade física:
- Peso= Altura = IMC:
- Tabaco; quanto?
- Cafeína; quanto?



PROJECTO DE INVESTIGAÇÃO: IDENTIFICAÇÃO EM FLUIDOS BIOLÓGICOS DE POSSÍVEIS BIOMARCADORES DE UMA FASE PRECOCE DA DOENÇA DE PARKINSON

Nº de Identificação: _____.; Idade: _____ Género: _____

Exame neurológico sumário

Sinais doença neurónio motor superior

..... Reflexo plantar:

Sinais doença neurónio motor inferior

.....
.....

Dados a colher do processo:

Confirmação antecedentes patológicos:

.....
.....
.....

- Nas análises clínicas, valor dos seguintes (referir data):

TGO

TGP

GGT

TP

TPPT

Creatinina

Ureia

Ácido úrico

Outros dados relevantes:

.....
.....
.....

Annex 3 - Patients and healthy controls Informed Consent

Consentimento Livre e Informado

Graça Maria Fernandes Baltazar, Carla Sofia Pais Fonseca e Luiza Rosado, Professoras da Faculdade de Ciências da Saúde da Universidade da Beira Interior, a realizar um trabalho de investigação com o tema “Identificação em Fluidos Biológicos de Possíveis Biomarcadores de uma Fase Precoce da Doença de Parkinson”, vêm solicitar a sua colaboração neste estudo. Este estudo implica a consulta do processo clínico de cada paciente e a utilização de uma pequena parte da colheita de sangue realizada como rotina durante o internamento para as análises necessárias ao estudo, não sendo feita colheita sanguínea adicional propositadamente para a investigação. É ainda requerida a recolha de uma amostra de saliva. Informo que a sua participação é voluntária, podendo desistir a qualquer momento sem que por isso venha a ser prejudicado nos cuidados de saúde prestados pelo CHCB, EPE; informo ainda que todos os dados recolhidos serão confidenciais.

Consentimento Informado - Investigador

Ao assinar esta página está a confirmar o seguinte:

- * Entregou esta informação
- * Explicou o propósito deste trabalho
- * Explicou e respondeu a todas as questões e dúvidas apresentadas pelo doente.

Nome do Investigador (Legível)

(Assinatura do Investigador)

___/___/___
(Data)

Consentimento Informado - Paciente

Ao assinar esta página está a confirmar o seguinte:

- * O Sr.(a) leu e compreendeu todas as informações desta informação, e teve tempo para as ponderar;
- * Todas as suas questões foram respondidas satisfatoriamente;
- * Se não percebeu qualquer das palavras, solicitou ao investigador que lhe fosse explicado, tendo este explicado todas as dúvidas;
- * O Sr. (a) recebeu uma cópia desta informação, para a manter consigo.

Nome do Doente (Legível)

(Assinatura do Doente ou Representante Legal)

___/___/___
(Data)

Annex 4 - BD™ CBA Human Inflammatory Cytokines Kit (BDCBAHICK) Procedure

Required materials

Reagents provided in the BDCBAHICK:

- Human Inflammatory Cytokine PE Detection Reagent
- Human Inflammatory Cytokine Standards
- Cytometer Setup Beads
- PE Positive Control Detector
- FITC Positive Control Detector
- Wash Buffer
- Assay Diluent
- Serum Enhancement Buffer

In addition, the following items are also required:

- BD FACSCalibur™ - a dual-laser flow cytometer equipped with a 488 nm and a 635 nm laser capable of distinguishing 576 nm, 660 nm, and >680 nm fluorescence.
- BD Falcon™ 12 × 75 mm sample acquisition tubes for a flow cytometer
- 15-mL conical, polypropylene tubes or equivalent
- FCAP Array software

Workflow overview

The overall workflow consists of the following steps:

1. Preparing Human Inflammatory Cytokines Standards
2. Mixing Human Inflammatory Cytokine Capture Beads
 - 3.1. Performing the Human Inflammatory Cytokine Assay
 - 3.2. Performing instrument setup with Cytometer Setup Beads, during the incubation
4. Acquire samples
5. Data analysis

First, we prepared and analyzed the standards, and within 12 hours, we proceed to samples preparation and analysis.

- **Step 1 - Preparing Human Inflammatory Cytokines Standards**


The Human Inflammatory Cytokines Standards are lyophilized. They were reconstituted and serially diluted immediately before mixing with the Capture Beads and the PE Detection Reagent.

We prepared fresh standards to run with the experiment.

Procedure to reconstitute and serially dilute the standards:

1. Open one vial of lyophilized Human Inflammatory Cytokine Standards. Transfer the standard spheres to a 15-mL polypropylene tube. Label the tube "Top Standard."
2. Reconstitute the standards with 2 mL of Assay Diluent.
 - a. Allow the reconstituted standard to equilibrate for at least 15 minutes at room temperature.
 - b. Gently mix the reconstituted protein by pipette only. Do not vortex or mix vigorously.
3. Label eight 12 × 75 mm tubes and arrange them in the following order: 1:2, 1:4, 1:8, 1:16, 1:32, 1:64, 1:128, and 1:256.
4. Pipette 300 µL of Assay Diluent in each of the 12 × 75 mm tubes.
5. Perform a serial dilution (S_Figure 1):
 - a. Transfer 300 µL from the Top Standard to the 1:2 dilution tube and mix thoroughly by pipette only. Do not vortex.
 - b. Continue making serial dilutions by transferring 300 µL from the 1:2 tube to the 1:4 tube and so on to the 1:256 tube.

S_Figure 1 - Serial dilution scheme from step 5



6. Prepare one 12 × 75-mm tube containing only Assay Diluent to serve as the 0 pg/mL negative control.

- **Step 2 - Mixing Human Inflammatory Cytokine Capture Beads**

Procedure to mix the beads:

1. Determine the number of assay tubes (including standards and controls) that are required for the experiment.
2. Vigorously vortex each Capture Bead suspension for 3 to 5 seconds before mixing.
Note: The antibody-conjugated beads will settle out of suspension over time. Vortex the vial immediately before taking a bead-suspension aliquot.
3. Add a 10- μ L aliquot of each Capture Bead, for each assay tube to be analyzed, into a single tube labeled "Mixed Capture Beads" (eg, 10 μ L of IL-8 Capture Beads \times 18 assay tubes = 180 μ L of IL-8 Capture Beads required).
4. Vortex the bead mixture thoroughly.

If the samples are serum or plasma, it is necessary resuspend the beads to reduce the chances of false positive results due to serum or plasma proteins.

Proceed to resuspend the Capture Beads in Serum Enhancement Buffer:

1. Centrifuge the mixed Capture Beads at 200g for 5 minutes.
2. Carefully aspirate and discard the supernatant.
3. Resuspend the mixed Capture Beads pellet in Serum Enhancement Buffer (equal to the volume removed in step 2) and vortex thoroughly.
4. Incubate the mixed Capture Beads for 30 minutes at room temperature, protected from light.

The mixed Capture Beads are ready to be transferred to the assay tubes. The excess mixed Capture Beads are discard.

- **Step 3 - Performing the Human Inflammatory Cytokine Assay. Performing instrument setup with Cytometer Setup Beads, during the incubation**

1. Vortex the mixed Capture Beads and add 50 μ L to all assay tubes.
2. Add 50 μ L of the Human Inflammatory Cytokine Standard dilutions to the control tubes as listed in S_Table 1.

S_Table 1 - Control tubes preparation.

Tube label	Concentration (pg/mL)	Standard dilution
1	0 (negative control)	No standard dilution (Assay Diluent only)
2	20	1:256
3	40	1:128
4	80	1:64
5	156	1:32
6	312,5	1:16
7	625	1:8
8	1250	1:4
9	2500	1:2
10	5000	Top Standard

3. Add 50 μ L of each unknown sample to the appropriately labeled sample tubes.
4. Incubate the assay tubes for 1.5 hours at room temperature, protected from light.
Note: Cytometer setup could be performed during this incubation, or during the incubation in step 8.
5. Add 1 mL of Wash Buffer to each assay tube and centrifuge at 200g for 5 minutes.
6. Carefully and consistently, aspirate and discard the supernatant, leaving approximately 100 μ L of liquid in each assay tube.
7. Add 50 μ L of the Human Inflammatory Cytokine PE Detection Reagent to all assay tubes. Gently agitate the tubes to resuspend the pellet.
8. Incubate the assay tubes for 1.5 hours at room temperature, protected from light.
9. Add 1 mL of Wash Buffer to each assay tube and centrifuge at 200g for 5 minutes.
10. Carefully aspirate and discard the supernatant from each assay tube.
11. Add 300 μ L of Wash Buffer to each assay tube to resuspend the bead pellet.

- **Step 4 - Acquire samples**

1. Acquire the samples on the flow cytometer.

To facilitate the sample analysis, we followed the guidelines present by the Instruction Manual:

- Acquire standards from lowest (0 pg/mL) to highest (Top Standard) concentration, followed by the test samples.
- Store all files (standards and samples) in a single folder.

- **Step 5 - Data analysis**

1. Use BD CellQuest software.
The data are presented in “Results” subsection.

Annex 5 - Results of cytokine measurements in PD and HC blood serum using BD™ CBA Human Inflammatory Cytokines Kit (BDCBAICK)

S_Table 2 - Results of serum cytokine measurements with BDCBAICK


Sample identification	FI					
	IL-12p70	TNF- α	IL-10	IL-6	IL-1B	IL-8
CN1	1,6	2,1	2,2	2,8	2,1	4,7
CN2	1,6	2,1	2,1	2,7	2,0	4,4
CN3	1,6	2,1	2,2	2,8	2,1	4,6
CN4	1,7	2,1	2,1	2,7	2,1	4,5
CN5	1,6	2,1	2,1	2,7	2,1	4,7
CN6	1,6	2,1	2,2	2,7	2,1	4,5
CN7	1,6	2,1	2,2	2,7	2,0	4,5
CN8	1,6	2,1	2,1	2,7	2,1	4,6
CN10	1,6	2,1	2,1	2,7	2,1	4,6
CN11	1,7	2,1	2,2	2,7	2,1	4,6
CN12	1,6	2,1	2,1	2,8	2,1	4,6
CN13	1,6	2,1	2,2	2,8	2,1	4,6
CN14	1,7	2,1	2,2	2,8	2,1	4,7
CN15	1,6	2,1	2,2	2,8	2,2	4,7
CN16	1,6	2,1	2,1	2,8	2,2	4,7
CN17	1,6	2,1	2,2	2,8	2,1	4,7
CN18	1,6	2,1	2,1	2,8	2,1	4,6
CN20	1,6	2,1	2,1	2,8	2,1	4,6
CN21	1,7	2,1	2,2	2,7	2,1	4,6
CN22	1,7	2,1	2,2	2,8	2,2	4,5
CN23	1,6	2,1	2,1	2,9	2,1	4,6
CN24	1,7	2,0	2,1	2,7	2,1	4,6
CN25	1,6	2,1	2,1	2,8	2,1	4,4
CN26	1,6	2,1	2,1	2,8	2,1	4,5
CN27	1,6	2,1	2,1	2,7	2,1	4,5
CN28	1,6	2,1	2,2	2,8	2,1	4,5
CN29	1,6	2,0	2,1	2,8	2,1	4,5
CN30	1,6	2,1	2,1	2,8	2,1	4,5
CN31	1,6	2,1	2,1	2,8	2,0	4,5
CN32	1,6	2,1	2,2	2,7	2,1	4,5
CN34	1,6	2,1	2,2	2,7	2,1	4,5

Clinical Characterization of Parkinson's Disease Patients Followed at CHCB:
Comparison with a control group


CN35	1,7	2,1	2,2	2,8	2,1	4,7
DP1	1,6	2,1	2,1	2,7	2,1	4,6
DP2	1,6	2,1	2,2	2,8	2,1	4,5
DP3	1,6	2,1	2,1	2,7	2,1	4,5
DP4	1,6	2,1	2,2	2,8	2,2	4,7
DP5	1,7	2,0	2,1	2,7	2,1	4,5
DP6	1,6	2,0	2,2	2,6	2,1	4,5
DP7	1,6	2,1	2,1	2,7	2,1	4,5
DP8	1,6	2,1	2,1	2,7	2,1	4,5
DP9	1,7	2,1	2,1	2,7	2,1	4,5
DP10	1,7	2,0	2,1	2,8	2,1	4,5
DP11	1,6	2,1	2,1	2,7	2,1	4,3
DP12	1,6	2,0	2,2	2,8	2,1	4,4
DP13	1,7	2,1	2,1	2,7	2,1	4,5
DP14	1,6	2,1	2,1	2,7	2,1	4,5
DP15	1,6	2,1	2,2	2,7	2,2	4,5
DP16	13,6	2,1	2,1	2,7	2,1	4,6
DP17	1,6	2,0	2,1	2,7	2,1	4,5
DP18	1,7	2,1	2,2	2,8	2,1	4,5
DP19	1,7	2,1	2,1	2,9	2,1	4,4
DP20	1,7	2,1	2,2	2,8	2,2	4,5
DP21	1,6	2,1	2,1	2,8	2,1	4,4
DP22	1,7	2,0	2,1	2,8	2,1	4,5
DP23	1,7	2,1	2,2	2,7	2,1	4,6
DP24	1,6	2,1	2,1	2,7	2,1	4,5
DP25	1,6	2,1	2,2	2,7	2,1	4,5
DP26	1,6	2,1	2,1	2,7	2,1	4,3
DP27	1,7	2,1	2,2	2,8	2,1	4,6
DP28	1,8	2,1	2,2	2,8	2,1	4,5
DP29	1,6	2,1	2,2	2,8	2,1	4,5
DP30	1,6	2,1	2,2	2,7	2,1	4,5
DP31	1,7	2,1	2,2	2,8	2,2	4,4
DP32	1,7	2,1	2,2	2,8	2,2	4,6
DP33	1,6	2,0	2,2	2,8	2,1	4,5
DP34	1,6	2,1	2,1	2,7	2,1	4,6
DP35	1,6	2,1	2,1	2,8	2,1	4,6
DP36	1,7	2,1	2,2	2,8	2,1	4,5
DP38	1,7	2,1	2,1	2,8	2,1	4,5
DP39	1,7	2,1	2,2	2,7	2,1	4,5

Annex 6 - Calibration curves from cytokines measurement with BDCBAHICK


S_Graph 1 - IL-12p70 calibration curve.




S_Graph 2 - TNF- α calibration curve.




S_Graph 3 - IL-10 calibration curve.




S_Graph 4 - IL-6 calibration curve.



S_Graph 5 - IL-18 calibration curve.



S_Graph 6 - IL-8 calibration curve.



Annex 7 - Normal ranges for laboratory variables

S_Table 3 - Laboratory variables normal ranges.


		Normal ranges	
		Male	Female
Hemogram ¹⁴	Hb (g/dL)	13,6 - 18,0	11,5 - 16,0
	MCV (fL)	80,0 - 97,0	
	MCHC (g/dL)	32,0 - 36,0	
	RDW (%)	11,5 - 15,0	
Leukogram ¹⁵	Leucocytes (10 ³ /uL)	4,0 - 10,0	
	Neutrophils (10 ³ /uL)	1,5 - 8,0	
	Lymphocytes (10 ³ /uL)	0,8 - 4,0	
	Monocytes (10 ³ /uL)	0,0 - 1,2	
	Eosinophils (10 ³ /uL)	0,0 - 0,3	
	Basophiles (10 ³ /uL)	0,0 - 0,3	
Renal Function ¹⁴	eGFR (mL/min/1,73m ²)	HC with sustained values below 60 were not included (criteria for CKD).	
Inflammatory (biochemical) parameters ¹⁴	CRP (mg/dL)	0-0,75	
	ESR (mm/H)	0 - 20	0 - 30
Oxidative stress parameters ¹⁴	Urate (mg/dL)	0,0 - 7,0	0,0 - 5,7

¹⁴ Hemogram values are according with Norma DGS 63/2011.


¹⁵ According with Clinical Pathology Laboratory of CHCB

Annex 8 - PD group and HC Inflammatory (biochemical), Leukogram, Oxidative Stress and Hemogram parameters - scatter plot graphs

Inflammatory (biochemical) parameters




S_Graph 7 - CRP from PD group and HC - scatter plot graphs.




S_Graph 8 - ESR from PD group and HC females (a) and males (b) - scatter plot graphs.


Leukogram parameters



S_Graph 9 - Leucocytes from PD group and HC - scatter plot graphs.




S_Graph 10 - Lymphocytes from PD group and HC - scatter plot graphs.




S_Graph 11 - Monocytes from PD group and HC - scatter plot graphs.

Oxidative Stress parameters




S_Graph 14 - Urate from PD group and HC females (a) and males (b) - scatter plot graphs.


Hemogram parameters



S_Graph 15 - MCV from PD group and HC - scatter plot graphs.



S_Graph 16 - MCHC from PD group and HC - scatter plot graphs.



S_Graph 17 - RDW from PD group and HC - scatter plot graphs.

Clinical Characterization of Parkinson's Disease Patients Followed at CHCB:
Comparison with a control group